ACE2 News and Research

RSS

Grapevine leaf extract inhibits SARS-CoV-2 and HSV-1 replication in the lab

Researchers in Italy have shown that leaf extract from the common grapevine – Vitis vinifera – exhibits significant antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

1 Jul 2021

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

In a recently published article scientists have provided a detailed description of the utility of mannose-specific lectins in preventing coronavirus infections. They have specifically explained how mannose-specific lectins derived from plants, algae, fungi, and bacteria selectively bind N-glycans present on the surface of viral spike protein and how such interactions can be medically utilized to control coronavirus transmission.

1 Jul 2021

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

A recent Diagnostics study discusses the specific antibody response that occurred in individuals after they had received the SARS-CoV-2 vaccine.

1 Jul 2021

Could peridomestic mammals act as zoonotic reservoirs for SARS-CoV-2?

In new research from researchers in the USA and Australia peridomestic mammals, which live in and around human habitations, have been investigated to ascertain how SARS-CoV-2 can affect species external to, but in close proximity to, the human population.

1 Jul 2021

Zinc-embedded polyamides inactivate SARS-CoV-2 and influenza A

The researchers show that the fabric retains its virus-inactivating property and stable zinc content over 50 standardized washes.

1 Jul 2021

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

The study, published in the journal Cell Reports, showed that the mutations in the virus, particularly the deletion of two amino acids H69/V70 seen in the Alpha variant (B.1.1.7), enables the virus to overcome weaknesses as it evolves.

30 Jun 2021

Study provides important insights into early stages of SARS-CoV-2 infection

Researchers in the UK have provided important new insights into the early stages of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Alpha (B.1.1.7) SARS-CoV-2 variant associated with more severe disease in hospitalized women

Researchers in the UK have conducted a study showing that infection with the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be associated with an increased risk of death or intensive care unit (ITU) admission among women, compared with non-B.1.1.7 infection.

29 Jun 2021

Cationic peptides inhibit SARS-CoV-2 cell entry

In a paper recently published in Pathogens, in silico affinity studies by researchers at the University of Illinois, USA, reveal several potential peptide binding sites required for HS-spike protein and ACE2-spike protein bond formation, and synthesis of suitable peptide inhibitors reveals impaired SARS-CoV-2 cell entry.

29 Jun 2021

Study explores structure, activity, and inhibition of TMPRSS2 implicated in SARS-CoV-2 activation

Researchers from Canada recently presented an efficient strategy for recombinant production of enzymatically active TMPRSS2 ectodomain, enabling enzymatic characterization and the 1.95 Å X-ray crystal structure. Their work is published on the bioRxiv* preprint server while awaiting peer-review.

29 Jun 2021

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

One of the key mutations seen in the 'Alpha variant' of SARS-CoV-2 - the deletion of two amino acids, H69/V70 - enables the virus to overcome chinks in its armor as it evolves, say an international team of scientists.

29 Jun 2021

Differences in monocyte subsets between severe COVID-19 and long COVID

Researchers in the United States and Costa Rica have identified differences in the proportions of monocyte subsets that occur in severe cases of coronavirus disease 2019 (COVID-19) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and post-acute sequelae of COVID-19 (PASC), often referred to as “Long COVID”.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won't protect against them.

25 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

ACE2 News and Research

Grapevine leaf extract inhibits SARS-CoV-2 and HSV-1 replication in the lab

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

Could peridomestic mammals act as zoonotic reservoirs for SARS-CoV-2?

Zinc-embedded polyamides inactivate SARS-CoV-2 and influenza A

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

Study provides important insights into early stages of SARS-CoV-2 infection

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

Alpha (B.1.1.7) SARS-CoV-2 variant associated with more severe disease in hospitalized women

Cationic peptides inhibit SARS-CoV-2 cell entry

Study explores structure, activity, and inhibition of TMPRSS2 implicated in SARS-CoV-2 activation

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

Differences in monocyte subsets between severe COVID-19 and long COVID

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Why SARS-CoV-2 delta variant is more infectious

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News